The efficacy of the healthy food containing an extract prepared from Actinidia arguta, in decreasing symptoms of pruritus in hemodialysis patients

The efficacy of the healthy food containing an extract prepared from Actinidia arguta, in decreasing symptoms of pruritus in hemodialysis patients - The efficacy of an water soluble extract prepared from Actinidia arguta in hemodialysis patients with pruritus

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005500

Enrollment

Registered

2011-04-25

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pruritus in hemodialysis patients

Interventions

tablets contain an water soluble extract prepared from Actinidia arguta

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, Age: Men and women 20 years old and older 2, Hemodialysis patients with symptomatic pruritus 3, Patients who don't need assist from others in their daily life 4, Level of IgE in the blood: 50 IU/ml and over 5, Patients who haven't had benefit of existing treatments for pruritus (antohistamin drug, steroid, etc.)

Exclusion criteria

Exclusion criteria: 1, Level of IgE in the blood: under 50 IU/mL 2, Patients with i-PTH of 500pg/ml and above in the past one month. 3, Patients who had parathyroidectomy in the past 6 months of int the study 4, Patients with allergy to kiwi fruits 5, Patients in asthma care. 6, Patients in the cancer treatment 7, Patients with a history of kidney transplant 8, Patients who are pregnant or to be pregnant within three months 9, Patients with severe mental disorder 10, Patients who are unsuitable to the study at a physician's discretion

Design outcomes

Primary

Measure	Time frame
1, Evaluate the effect in decreasing symptoms of pruritus measured by VAS(Visual analogue scale). 2, Changes in the level of IgE in the blood 3, Changes in the number of eosinophils in the blood 4, Changes in the level of ECP (Eosinophil Cationic Protein)	—

Secondary

Measure	Time frame
1, Changes in the level of phosphorus and potassium 2, Changes in the level of intact-PTH 3, Changes in the value of blood test and urine test	—

Countries

Japan

Contacts

Public ContactYurina Ono

Amano Memorial Clinic Center for clinical trial supporting

+81-52-521-2788

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026